title: The effect of trimetazidine on ventricular repolarization indexes and left ventricular diastolic function in patients with coronary slow flow.
abstract: OBJECTIVE
  Coronary slow flow (CSF) is associated with an increased incidence of adverse cardiovascular events. Previous studies have shown increases in P wave dispersion, QT dispersion, and the Tp-e/QT ratio, and a prolonged Tp-e interval, as well as left ventricular diastolic dysfunction in patients with CSF. We aimed to examine the effect of trimetazidine (TMZ) on these arrhythmia predictors and diastolic function of the left ventricle.
  
  
  METHODS
  Our study included 30 patients with CSF and 30 individuals with normal coronary arteries. Twelve-lead ECG and echocardiography were used to evaluate patients before and 4 weeks after treatment with TMZ.
  
  
  RESULTS
  Compared with the control group, corrected Pd (29.3±9.1 vs. 22.9±11.6, P=0.022), corrected QT dispersion (32.3±11.1 vs. 27.4±6.8, P=0.032), corrected Tp-e interval (103.1±18.6 vs. 93.4±11.5, P=0.017), and Tp-e/QT ratio (0.236±0.03 vs. 0.210±0.02, P=0.001) were significantly longer, and the E/A ratio (0.905±0.16 vs. 0.986±0.12, P=0.037) and the mean Em/Am ratio (0.918±0.19 vs. 1.095±0.20, P=0.006) were lower in patients with CSF. Corrected Pd, corrected Tp-e interval, and the Tp-e/QT ratio were significantly decreased (29.3±9.12 vs. 22.5±9.20, P=0.022; 97.3±16.6 vs. 88.2±16.4, P=0.031; 0.22±0.03 vs. 0.20±0.31, P=0.042 respectively), and left ventricle mitral annular mean Em/Am velocity was significantly increased (0.918±0.19 vs. 1.095±0.20, P=0.017) after treatment with TMZ.
  
  
  CONCLUSIONS
  CSF may be related to increased P wave and QT dispersion, a prolonged Tp-e interval, and Tp-e/QT ratio, in addition to impaired diastolic filling. TMZ may be useful in restoring these findings.
authors.affiliation: Department of Cardiology, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey.
authors.forename: Arif
authors.initials: A
authors.lastname: Suner
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cetin
mesh_terms: D000200:Action Potentials; D000328:Adult; D001145:Arrhythmias, Cardiac / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D016022:Case-Control Studies; D002932:Cineangiography; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D003971:Diastole; D015150:Echocardiography, Doppler; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006352:Heart Ventricles / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D054318:No-Reflow Phenomenon / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D014665:Vasodilator Agents; D014292:Trimetazidine